Found 551 clinical trials
SCB-2019 as COVID-19 Vaccine
This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects. Each study vaccine dose level will be evaluated with and without adjuvant.
- 0 views
- 05 Aug, 2020
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
- 0 views
- 05 Aug, 2020
GNOS-PV02 Personalized Neoantigen Vaccine INO-9012 and Pembrolizumab in Subjects With Advanced HCC
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
- 0 views
- 16 Feb, 2024
- 3 locations
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine
In December 2019, viral pneumonia caused by a novel beta-coronavirus (Covid-19) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat and prevent severe Covid-19 pneumonia. Based on detailed analysis of …
- 0 views
- 16 Feb, 2024
- 3 locations
Safety and Immunogenicity Study of GX-19 a COVID-19 Preventive DNA Vaccine in Healthy Adults
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
- 0 views
- 16 Feb, 2024
- 1 location
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and to assess the T-cell response.
- 0 views
- 16 Feb, 2024
- 1 location
- 0 views
- 14 Mar, 2022
- 1 location
PQ Test Trial ( Do not edit)
Primary Objective:Primary population (former smokers cohort):Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPDSecondary Objectives:Primary population (former smokers cohort):Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPDEvaluate the efficacy …
- 0 views
- 01 Apr, 2024
- 4 locations
